Holen Sie sich die Stockscreener-App
8.51
0.12%
-0.010
Schlusskurs vom Vortag:
$8.52
Offen:
$8.51
24-Stunden-Volumen:
979.15K
Relative Volume:
1.59
Marktkapitalisierung:
$385.47M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-17.37
EPS:
-0.49
Netto-Cashflow:
$-27.23M
1W Leistung:
-0.12%
1M Leistung:
+95.18%
6M Leistung:
+43.51%
1J Leistung:
-14.47%
1-Tages-Spanne:
$8.51
$8.53
1-Wochen-Bereich:
$8.50
$8.54
52-Wochen-Spanne:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
646-885-8505
Adresse
202 CARNEGIE CENTER, PRINCETON, NY
Vergleichen Sie YMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.51 | 387.14M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSEWOW), BankFinancial Corporation (NasdaqBFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nas - Morningstar
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Brookline Capital Management - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
11 Best Short-Term Stocks to Invest in - Insider Monkey
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y-mAbs Therapeutics Q2 Earnings: Revenue Meets Expectations, EPS Below Consensus - AInvest
Y-mAbs Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com Canada
Y-mabs sold to Serb Pharmaceuticals for USD 412m - medwatch.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders - The Joplin Globe
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders | FinancialContent - FinancialContent
Y-mAbs (YMAB) Q2 Revenue Falls 14% - The Motley Fool
Y-mAbs Therapeutics, Inc. SEC 10-Q Report - TradingView
Y-mAbs Therapeutics, Inc. Q2 2025 Financial Results - TradingView
Y-mAbs Q2 rev. $19.5mln, exceeds guidance, acquires Y-mAbs for $412mln. - AInvest
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Acquisition: SERB Pays 105% Premium in $412M Deal While Q2 Revenue Exceeds Guidance - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - PR Newswire
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast - 富途牛牛
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc.YMAB - Business Wire
Y-mAbs Q2 2025 Earnings Tomorrow: Key Updates Coming Amid SERB Pharma Transaction - Stock Titan
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
BSR REIT ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS - The Globe and Mail
YmAbs Therapeutics' 103.3% Surge: A Sustainable Bull Case or a Volatile Flash in the Pan? - AInvest
Y-mAbs Therapeutics Stock Surges 103.3% on Acquisition Deal with SERB Pharmaceuticals - AInvest
Y-mAbs Therapeutics: A Biotech M&A Deal that Highlights the Value and Challenges of the Industry - AInvest
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A - Seeking Alpha
Oppenheimer Downgrades Y-mAbs Therapeutics to Market Perform From Outperform, Adjusts Price Target to $3 From $4 - MarketScreener
Canaccord Genuity Downgrades Y-mAbs Therapeutics to Hold From Buy, Adjusts Price Target to $8.60 From $26 - MarketScreener
SERB Pharma to acquire Y-mAbs Therapeutics for $412m - World Pharmaceutical Frontiers
Wedbush Downgrades Y-mAbs Therapeutics to Neutral From Outperform, Cuts Price Target to $8.60 From $18 - MarketScreener
Y-mAbs Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
SERB bets on rare cancer drug in $412 million deal for Y-mAbs - The Pharma Letter
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. - Mugglehead Magazine
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord - TipRanks
Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition - Investing.com Canada
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline - TipRanks
Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics - TipRanks
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):